Physician profile
Amy Harrison
NPI 1962436782
$286.99
in general payments reported to CMS, 2019-2025
12 companies · $65.73 in 2025
The $65.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $106 · 2024: $116 · 2025: $65.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.83 | 2023 | Wavewriter Alpha Prime 16 |
| Becton, Dickinson and Company | $30.22 | 2024 | Bd Onclarity |
| Abbvie INC. | $29.86 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.12 | 2025 | |
| Dexcom, INC. | $27.18 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $24.73 | 2024 | Jot Dx |
| Sumitomo Pharma America, INC. | $21.64 | 2025 | Gemtesa |
| Aspira Women'S Health INC | $19.92 | 2023 | Ova1 |
| Pfizer INC. | $17.84 | 2024 | |
| Ascensia Diabetes Care US INC. | $15.97 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.94 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $15.74 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.